2023
[18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial
Koh E, Gan H, Senko C, Francis R, Ebert M, Lee S, Lau E, Khasraw M, Nowak A, Bailey D, Moffat B, Fitt G, Hicks R, Coffey R, Verhaak R, Walsh K, Barnes E, De Abreu Lourenco R, Rosenthal M, Adda L, Foroudi F, Lasocki A, Moore A, Thomas P, Roach P, Back M, Leonard R, Scott A. [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. BMJ Open 2023, 13: e071327. PMID: 37541751, PMCID: PMC10407346, DOI: 10.1136/bmjopen-2022-071327.Peer-Reviewed Original ResearchConceptsFET PETPositron emission tomographyPrimary central nervous system cancerTumor progressionCentral nervous system cancerL-tyrosine positron emission tomographyFET-PET imagingPhase II studyCo-primary outcomesProgression-free survivalMaximal safe resectionPost-chemotherapy treatmentNervous system cancersHealth economic impactHuman Research Ethics CommitteePatterns of failureTrue tumor progressionGood clinical practiceDeclaration of HelsinkiRadiological progressionConcurrent chemoradiationInitial surgeryPostoperative radiotherapyII studyOverall survivalCorrecting the drug development paradigm for glioblastoma requires serial tissue sampling
Singh K, Hotchkiss K, Parney I, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen P, Minniti G, Colman H, Cloughesy T, Mehta M, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley S, Ashley D, Kumthekar P, Verhaak R, Chalmers A, Patel A, Watts C, Fecci P, Batchelor T, Weller M, Vogelbaum M, Preusser M, Berger M, Khasraw M. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nature Medicine 2023, 29: 2402-2405. PMID: 37488293, DOI: 10.1038/s41591-023-02464-8.Peer-Reviewed Original Research
2021
Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription
Zhu Y, Gujar A, Wong C, Tjong H, Ngan C, Gong L, Chen Y, Kim H, Liu J, Li M, Mil-Homens A, Maurya R, Kuhlberg C, Sun F, Yi E, deCarvalho A, Ruan Y, Verhaak R, Wei C. Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription. Cancer Cell 2021, 39: 694-707.e7. PMID: 33836152, PMCID: PMC8119378, DOI: 10.1016/j.ccell.2021.03.006.Peer-Reviewed Original ResearchConceptsGenome-wide activationSingle-molecule resolutionMobile enhancerChromatin interactionsChromosomal interactionsChromatin contactsTranscription controlChromosomal transcriptionChromosomal targetsTranscriptional programsTranscriptional enhancersChromosomal genesChIA-PETGene transcriptionCancer genomesInteraction networksDNA functionH3K27ac signalProstate cancer cellsCircular DNAEcDNAsExpression levelsCancer cellsOncogenic alterationsTranscription
2018
Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
deCarvalho A, Kim H, Poisson L, Winn M, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam D, Petricoin E, Chin L, Mikkelsen T, Verhaak R. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nature Genetics 2018, 50: 708-717. PMID: 29686388, PMCID: PMC5934307, DOI: 10.1038/s41588-018-0105-0.Peer-Reviewed Original ResearchConceptsExtrachromosomal DNA elementsDNA elementsChromosomal DNA alterationsDNA alterationsSomatic driver alterationsGenomic heterogeneitySingle nucleotide variantsOffspring cellsDiscordant inheritanceExtrachromosomal elementsEcDNAsGBM evolutionOncogenic potentialGBM samplesInheritance patternChromosomal alterationsSelection dynamicsModel systemCell culturesOrthotopic xenograft modelDriver alterationsXenograft modelOncogene amplificationCellsGlioblastoma
2017
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho A, Lyu S, Li P, Li Y, Barthel F, Cho H, Lin Y, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé C, Olar A, Lan Z, Finocchiaro G, Phillips J, Berger M, Gabrusiewicz K, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho R, Muller F, Heimberger A, Sulman E, Nam D, Verhaak R. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 2017, 32: 42-56.e6. PMID: 28697342, PMCID: PMC5599156, DOI: 10.1016/j.ccell.2017.06.003.Peer-Reviewed Original Research
2012
Studying a Complex Tumor
Zheng S, Chheda M, Verhaak R. Studying a Complex Tumor. The Cancer Journal 2012, 18: 107-114. PMID: 22290264, PMCID: PMC3342695, DOI: 10.1097/ppo.0b013e3182431c57.Peer-Reviewed Original ResearchConceptsGenomic alterationsRecurrent genomic alterationsDNA copy numberGenomic studiesGenomic researchCopy numberExpression signaturesGenomic abnormalitiesGlioblastoma multiforme samplesExpression subtypesNew insightsGenesGlioblastoma multiformeGlioblastoma multiforme therapyHeterogeneous diseaseHigh specificityAlterationsTP53IDH1Identification